Bristol-Myers Squibb - Corporate Responsibility


	Patient Assistance Programs
	Fighting AIDS in Africa
	Bristol-Myers Squibb Foundation & Corporate Philanthropy
	Product Integrity
	Sustainability: Our Plan for Responsible Growth
	Environment, Health & Safety Policy
	Medical Education Grants And Charitable Contributions
	Clinical Outcomes And Research Grants
	Position On Key Issues

» BMS.com Home » Corporate Responsibility » Product Integrity

Product Integrity

Bristol-Myers Squibb Company (BMS) is committed to ensuring the safety and integrity of its products as part of its pledge to extend and enhance human life. Counterfeit and tampered products represent a threat to the Bristol-Myers Squibb pledge to provide our customers with the safest, most effective and highest quality products. The World Health Organization (WHO) estimates that up to 10% of medications consumed globally are counterfeit or substandard, putting patient safety at significant risk¹. There is no single solution to this issue; however, Bristol-Myers Squibb has taken the following actions in order to further ensure patient safety:

Creation of a specialized team spanning all business units to address counterfeiting issues.
Implementation of product security technology to make our packaging and products less vulnerable to counterfeiting.
Participation with industry coalitions and organizations addressing this issue.
Collaboration with supply chain entities on product security matters.

Food and Drug Administration >>
Partnership for Safe Medicines >>
Buy Safe Drugs >>
PhRMA Safety >>

¹World Health Organization: Regional Office for the Western Pacific. Counterfeit Medicines: Some Frequently Asked Questions – May 2005. http://www.wpro.who.int/media_centre/fact_sheets/fs_20050506.htm

[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.